ISSN:
1013-9826
Source:
Scientific.Net: Materials Science & Technology / Trans Tech Publications Archiv 1984-2008
Topics:
Mechanical Engineering, Materials Science, Production Engineering, Mining and Metallurgy, Traffic Engineering, Precision Mechanics
Notes:
Therapeutic angiogenesis by localized delivery of angiogenic factors is a promisingapproach to treat patients with cardiovascular disease and to engineer large tissues. Vascularendothelial growth factor (VEGF) is the most common and biologically active form of the VEGFfamily, which acts as a mitogen to endothelial cells and is capable of specific binding to heparin.However, when VEGF is administered via bolus injection, it can be widely distributed, and itsconcentration is likely to be within the effective window for only a short time period due to rapiddegradation. Delivery of angiogenic factors, using controlled drug delivery strategies, offers greatpotential to promote angiogenesis at a specific site while reducing the unwanted side effects thatmay occur with systemic delivery. We now report on the sustained release of VEGF from alginategels, modified with a heparin-binding peptide. Briefly, a small peptide with the sequence ofG5K(βA)FAKLAARLYRKA, which is known to specifically interact with heparin, was chemicallyconjugated to alginate, and the peptide-modified alginate formed gels after mixing with heparin andVEGF. The release rate of VEGF from the gels slowed in vitro for over 45 days, compared withrelease from non-modified alginate gels. This result suggests potential applications of alginate gelsin promoting angiogenesis for therapeutic purposes, as well as for tissue engineering
Type of Medium:
Electronic Resource
URL:
http://www.tib-hannover.de/fulltexts/2011/0528/01/54/transtech_doi~10.4028%252Fwww.scientific.net%252FKEM.342-343.517.pdf
Permalink